WallStreetZenWallStreetZen

NYSE: TEVA
Teva Pharmaceutical Industries Ltd Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

TEVA past revenue growth

How has TEVA's revenue growth performed historically?
Company
6.17%
Industry
10.11%
Market
17.29%
TEVA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TEVA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TEVA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TEVA earnings and revenue history

Current Revenue
$15.8B
Current Earnings
-$559.0M
Current Profit Margin
-3.5%

TEVA Return on Equity

Current Company
-7.6%
Current Industry
15.4%
Current Market
188%
TEVA's Return on Equity (-7.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when TEVA announces earnings.

TEVA Return on Assets

Current Company
-1.3%
Current Industry
3.4%
TEVA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

TEVA Return on Capital Employed

Current Company
1.57%
Current Industry
5.1%
TEVA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TEVA vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
TEVA$15.85B$1.64B-$559.00M-2.81%N/A
VTRS$15.43B$3.52B$54.70M+6.17%-40.84%
NBIX$1.89B$358.00M$249.70M+33.13%+61.92%
RDY$2.99B$904.61M$547.73M+6.52%N/A
CTLT$4.10B-$754.00M-$1.30B+10.50%N/A
View Top Pharmaceutical Stocks

TEVA earnings dates

Next earnings date
May 1, 2024

Teva Pharmaceutical Industries Earnings & Revenue FAQ

What were TEVA's earnings last quarter?

On Invalid Date, Teva Pharmaceutical Industries (NYSE: TEVA) reported Q4 2023 earnings per share (EPS) of $0.38, up 132.2% year over year. Total Teva Pharmaceutical Industries earnings for the quarter were $429.00 million. In the same quarter last year, Teva Pharmaceutical Industries's earnings per share (EPS) was -$1.18.

If you're new to stock investing, here's how to buy Teva Pharmaceutical Industries stock.

What was TEVA's earnings growth in the past year?

As of Q2 2024, Teva Pharmaceutical Industries's earnings has grown year over year. Teva Pharmaceutical Industries's earnings in the past year totalled -$559.00 million.

What is TEVA's earnings date?

Teva Pharmaceutical Industries's earnings date is Invalid Date. Add TEVA to your watchlist to be reminded of TEVA's next earnings announcement.

What was TEVA's revenue last quarter?

On Invalid Date, Teva Pharmaceutical Industries (NYSE: TEVA) reported Q4 2023 revenue of $4.46 billion up 14.75% year over year. In the same quarter last year, Teva Pharmaceutical Industries's revenue was $3.88 billion.

What was TEVA's revenue growth in the past year?

As of Q2 2024, Teva Pharmaceutical Industries's revenue has grown 6.17% year over year. This is 3.94 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.11%. Teva Pharmaceutical Industries's revenue in the past year totalled $15.85 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.